Physiomics Share News (PYC)

Physiomics Expects Annual Loss To Be "Materially Reduced"

LONDON (Alliance News) - Physiomics PLC said Thursday it is trading "ahead of market expectations" for its financial year to the end of June.The company, which provides technology

Physiomics Raises GBP525,000 Via Placing For Expansion (ALLISS)

LONDON (Alliance News) - Physiomics PLC on Wednesday said that it raised GBP525,000 through share placing to grow the business and expand its client base.The biotechnology company issued at

Physiomics Awarded New GBP68,000 Innovate UK Grant For Cancer Project

LONDON (Alliance News) - Physiomics PLC said Wednesday it has been awarded a new Innovate UK Grant worth GBP68,000 for a prostate cancer -

Physiomics Successfully Completes Innovate UK Grant Project

LONDON (Alliance News) - Physiomics PLC said Monday it has successfully completed the Innovate UK grant cancer treatment project, receiving in funding the

Physiomics makes 'good progress' towards objectives

(ShareCast News) - Physiomics announced on Wednesday that it is making good progress towards the strategic objectives announced in its most recent full year results, posted on 27 October 2016. The AIM-traded firm announced an initial payment by Sareum on 5 December, for modelling carried out by the

Physiomics receives Innovate UK grant for cancer treatment project

(ShareCast News) - Systems biology company Physiomics confirmed on Friday that is has been awarded the Innovate UK grant as part of its Biomedical Catalyst 2016 Feasibility Study Competition that was the subject of a provisional announcement on 22 November. The AIM-traded firm said the proposed proj

Physiomics Provisionally Awarded Innovate UK Grant

Physiomics Annual Loss Widens After Incurring Additional Costs

Physiomics Signs Two Extensions On Virtual Tumour Project

Physiomics Appoints Andrew Clayden As Part-Time Head Of Finance

James Millen takes the helm at Physiomics

(ShareCast News) - Physiomics had a new man at the helm on Monday, confirming Dr James Millen was taking the reins as CEO with immediate effect. The AIM-traded company said Millen, known as Jim, brought experience of drug development and licensing deals in global pharmaceutical companies with him.

Physiomics Names James Millen As Chief Executive

Physiomics Inks Further Contract With Speciality Pharma Customer

Physiomics To Buy BioMoti And Raise Funds As CEO Steps Down (ALLISS)